This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06445075 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Scholar Rock, Inc. |
| Enrollment | 102 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Overweight and Obesity |
| Interventions | Apitegromab; Placebo; Tirzepatide |
| Start | May 21, 2024 |
| Primary completion | Mar 4, 2025 |
| Study completion | Jun 17, 2025 |
| Results posted | Not yet |
| Registry last updated | Jan 23, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change from Baseline in total Lean Body Mass (kg) at 24 weeks | Baseline and 24 weeks |
10 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.
More trials of Apitegromab
Research area: Related non-peptide compounds. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.